Gabelli & Company Highlights 6 Potential Gilead Sciences (GILD) Takeover Targets
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/28/2026
- Wall St slips as oil spikes after Trump rejects Iran peace proposal
- S&P 500 breadth hits lowest level since dot-com bubble, Goldman says
- Nvidia’s AI dominance funds historic $150 billion buyback
- MongoDB stock drops 15% as CEO Desai resigns for Meta
- Jefferies cuts Roblox to Underperform, says rally is too optimistic
- Oppenheimer sees AI software winners as focus shifts to ROI
- Exclusive-Activist Jana pushes Fiserv to accelerate cost cuts and tap Palantir
- Bloom Energy shares fall on Oracle project halt
- Cantor Fitzgerald Starts Lexicon Pharmaceuticals (LXRX) at Overweight
- S&P 500 breadth hits lowest level since dot-com bubble, Goldman says
Incyte (INCY) Seen Back of Gilead's (GILD) Takeover Target List Following Disappointing Momelotinib Data - Leerink
November 17, 2016 8:24 AM ESTLeerink Partners analyst Geoffrey Porges says Incyte (NASDAQ: INCY) is back on the list of Gilead Sciences' (NASDAQ: GILD) takeover targets after Gilead's disappointing phase III data for their JAK 1/2 inhibitor momelotinib in myelofibrosis.
"One consequence of this disappointment, however, is that it does restore INCY to the list of... More
Incyte (INCY) PT Bumped to $115 at Leerink as Gilead's (GILD) Momelotinib Disappoints
November 17, 2016 8:12 AM ESTLeerink Partners analyst Michael Schmidt reiterated an Outperform rating and bumped his price target on Incyte (NASDAQ: INCY) to $115.00 (from $101.00) as Gilead Sciences' (NASDAQ: GILD) momelotinib disappoints.
Schmidt commented, "Today GILD (MP) reported top-line results from two Phase III... More
Gilead Sciences (GILD) Announces Momelotinib Phase 3 Met Primary Endpoint in Myelofibrosis; Secondary Endpoint Missed
November 16, 2016 4:17 PM ESTGilead Sciences, Inc. (Nasdaq: GILD) announced top-line results from two Phase 3 clinical trials (SIMPLIFY 1 and 2) evaluating momelotinib, an investigational inhibitor of Janus kinase (JAK) compared to ruxolitinib or best alternative therapy (BAT) in patients with myelofibrosis. The SIMPLIFY-1 study achieved its pre-specified primary endpoint of non-inferiority to ruxolitinib for splenic response rate at Week 24 (SRR24), defined as the percentage of patients experiencing a 35 percent reduction in spleen volume (momelotinib: 26.5%; ruxolitinib: 29.0%; 95 percent CI: -11.2% to +5.6%; p=0.011).
Non-inferiority was not achieved for the key secondary endpoint of response rate in total symptom score (TSS). Greater... More
